<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2
(AMENDMENT NO. ___)(1)
GENOME THERAPEUTICS CORPORATION
-------------------------------
(Name of Issuer)
COMMON STOCK
------------------------------
(Title of Class of Securities)
372430 10 8
--------------
(CUSIP Number)
March 24, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ X / Rule 13d-1(c)
/ / Rule 13d-1(d)
- ---------------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, SEE the
NOTES).
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 2 OF 7 PAGES
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BIOTECHNOLOGY VALUE FUND, L.P.
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / X /
of a Group (See Instructions) (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
DELAWARE
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 0
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With: 824,763
--------------------------------------------------
(7) Sole Dispositive Power
0
--------------------------------------------------
(8) Shared Dispositive Power
824,763
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
824,763
- -------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
4.5%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
PN
- -------------------------------------------------------------------------------
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 3 OF 7 PAGES
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BVF PARTNERS L.P.
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / X /
of a Group (See Instructions) (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
DELAWARE
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 0
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With: 1,552,089
--------------------------------------------------
(7) Sole Dispositive Power
0
--------------------------------------------------
(8) Shared Dispositive Power
1,552,089
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,552,089
- -------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.5%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
PN
- -------------------------------------------------------------------------------
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 4 OF 7 PAGES
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BVF INC.
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / X /
of a Group (See Instructions) (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
DELAWARE
- -------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 0
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With: 1,769,285
--------------------------------------------------
(7) Sole Dispositive Power
0
--------------------------------------------------
(8) Shared Dispositive Power
1,769,285
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,769,285
- -------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
9.6%
- -------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
IA, CO
- -------------------------------------------------------------------------------
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 5 OF 7 PAGES
- -------------------------------------------------------------------------------
ITEM 1.
(a) Name of Issuer
Genome Therapeutics Corp.
---------------------------------------------------------------------
(b) Address of Issuer's Principal Executive Offices
100 Beaver Street
Waltham, MA 02154
---------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
This schedule is being filed on behalf of the following persons*:
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) BVF Partners, L.P. ("Partners")
(iii) BVF Inc. ("BVF Inc.")
* Attached as Exhibit A is a copy of an agreement between the
Persons filing (as specified hereinabove) that this Schedule 13G
is being filed on behalf of each of them.
(b) Address of Principal Business Office or, if none, Residence
The principal business office of the persons comprising the group
filing this Schedule 13G is located at 227 West Monroe Street, Suite 4800,
Chicago, Illinois 60606.
(c) Citizenship
BVF: a Delaware limited partnership
Partners: a Delaware limited partnership
BVF Inc. a Delaware corporation
(d) Title of Class of Securities
The class of securities beneficially owned by the persons filing
this statement is common stock.
(e) CUSIP Number
372430 10 8
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(c),
CHECK THIS BOX /x/
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 6 OF 7 PAGES
- -------------------------------------------------------------------------------
ITEM 4. OWNERSHIP
The information in items 1 and 5 through 11 on the cover pages
(pp. 2-4) on Schedule 13G is hereby incorporated by reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following. / /
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
BVF shares voting and dispositive power over the shares of the Stock it
beneficially owns with Partners. Partners and BVF Inc. share voting and
dispositive power over the shares of the Stock they beneficially own with, in
addition to BVF, certain managed accounts on whose behalf Partners, as
investment manager, purchased such shares. BVF Inc. also shares voting and
dispositive power over the shares of the Stock they beneficially own with, in
addition to BVF and Partners, certain other managed accounts on whose behalf
BVF, Inc., as investment manager, purchased such shares. None of the
managed accounts individually own more than 5% of the Stock of the Issuer.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
<PAGE>
CUSIP No. 372430 10 8 13G PAGE 7 OF 7 PAGES
- -------------------------------------------------------------------------------
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and are held in
the ordinary course of business and were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: March 24, 1999
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the
information required by Schedule 13G, to which this Agreement is attached as
an exhibit, is filed on behalf of each of them. The undersigned further agree
that any amendments or supplements thereto shall also be filed on behalf of
each of them.
Dated: March 24, 1999
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-----------------------------
Mark N. Lampert
President
